Trending...
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
- Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
- David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
Eve Wellness located in SF offers the first FDA-approved ultrasound screening technology specifically designed for detecting cancer in dense breast tissue.
SAN FRANCISCO - ncarol.com -- Eve Wellness, a San Francisco-based breast cancer screening clinic, is leading the charge in breast cancer screening by providing women the opportunity to get screened earlier, at any age, without a doctor referral, using their FDA-Approved GE ABUS ultrasound technology, powered by FDA-Approved AI (artificial intelligence), all without radiation. This comes on the heels of the FDA's new mandate, announced on March 9, 2023, requiring all mammography facilities to report breast density information and enhance communications with patients and providers.
The FDA's move is important because the risk of breast cancer is of real concern to many patients, said Dr. Harold Burstein, a medical oncologist at the Dana-Farber Cancer Institute in Boston and a professor at Harvard Medical School. "The identification of dense breast tissue can be a marker of slightly greater risk of getting breast cancer, and it may need additional breast imaging," said Burstein, who likened the challenge of reading mammograms to "looking through frosted glass."
More on ncarol.com
Breast density has been identified as a risk factor for breast cancer, and the FDA's new mandate aims to increase awareness and understanding of this risk. The mandate requires mammography facilities to provide patients with information about their breast density and the impact it can have on the accuracy of mammograms. Facilities are also required to communicate the findings with healthcare providers and provide recommendations for additional screening options, such as breast ultrasound.
"Today's action represents the agency's broader commitment to support innovation to prevent, detect and treat cancer," said Hilary Marston, M.D., M.P.H., FDA's Chief Medical Officer. "Since 1992, the FDA has worked to ensure patients have access to quality mammography. The impact of the Mammography Quality Standards Act on public health has been significant, including a steep decrease in the number of facilities that do not meet quality standards. This means that more women have access to consistent, quality mammography. We remain committed to advancing efforts to improve the health of women and strengthen the fight against breast cancer."
At Eve Wellness, breast ultrasound is the best option for women with dense breast tissue. Their GE ABUS ultrasound technology, powered by AI, can detect breast cancer at an earlier stage and without the use of radiation. With physician-read results back in less than 48 hours, Eve Wellness provides women with quick results, reducing anxiety and enabling early intervention.
More on ncarol.com
"Breast cancer claims the lives of nearly 43,000 women annually, and early detection is key to improving outcomes. Eve is on a mission to fill the void in breast cancer screening," said Brendan Foley, Co-Founder at Eve Wellness. "We are proud to lead the change in breast screening by providing women with access to the latest technology and empowering them to take control of their breast health."
Eve Wellness is committed to providing women with the best possible breast cancer screening options and is a game-changer in the fight against breast cancer. With the FDA's new mandate, women can feel more informed and empowered in their breast health decisions, and Eve Wellness is here to support them every step of the way.
For more information on Eve Wellness and their breast cancer screening services, visit their website at https://www.myevewellness.com/.
The FDA's move is important because the risk of breast cancer is of real concern to many patients, said Dr. Harold Burstein, a medical oncologist at the Dana-Farber Cancer Institute in Boston and a professor at Harvard Medical School. "The identification of dense breast tissue can be a marker of slightly greater risk of getting breast cancer, and it may need additional breast imaging," said Burstein, who likened the challenge of reading mammograms to "looking through frosted glass."
More on ncarol.com
- Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
- David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
- "Phinge Unveil™" Coming to Las Vegas to Showcase Netverse Patented Verified App-less Platform, AI & Modular Hardware Including Developer Conferences
- Elizabeth McLaughlin, Founder and CEO of Red Wagon Group, named 2026 Presidential Leadership Scholar
- U.S. Congressional Candidate Peter Coe Verbica on America's Asymmetric Crisis
Breast density has been identified as a risk factor for breast cancer, and the FDA's new mandate aims to increase awareness and understanding of this risk. The mandate requires mammography facilities to provide patients with information about their breast density and the impact it can have on the accuracy of mammograms. Facilities are also required to communicate the findings with healthcare providers and provide recommendations for additional screening options, such as breast ultrasound.
"Today's action represents the agency's broader commitment to support innovation to prevent, detect and treat cancer," said Hilary Marston, M.D., M.P.H., FDA's Chief Medical Officer. "Since 1992, the FDA has worked to ensure patients have access to quality mammography. The impact of the Mammography Quality Standards Act on public health has been significant, including a steep decrease in the number of facilities that do not meet quality standards. This means that more women have access to consistent, quality mammography. We remain committed to advancing efforts to improve the health of women and strengthen the fight against breast cancer."
At Eve Wellness, breast ultrasound is the best option for women with dense breast tissue. Their GE ABUS ultrasound technology, powered by AI, can detect breast cancer at an earlier stage and without the use of radiation. With physician-read results back in less than 48 hours, Eve Wellness provides women with quick results, reducing anxiety and enabling early intervention.
More on ncarol.com
- Jones Sign Rebrands as Jones to Reflect Growth, Innovation, and Expanded Capabilities
- Helping high-functioning women reduce mental load by redesigning broken life systems
- $1 Million Share Repurchase Signals Confidence as Off The Hook YS Scales a Tech-Driven Platform in the $57 Billion U.S. Marine Market
- Trends Journal's Top Trends of 2026
- Tatt:Magic Unveils Breakthrough Tattoo Recovery System with Faster Healing, No Itch, and Vibrant Results
"Breast cancer claims the lives of nearly 43,000 women annually, and early detection is key to improving outcomes. Eve is on a mission to fill the void in breast cancer screening," said Brendan Foley, Co-Founder at Eve Wellness. "We are proud to lead the change in breast screening by providing women with access to the latest technology and empowering them to take control of their breast health."
Eve Wellness is committed to providing women with the best possible breast cancer screening options and is a game-changer in the fight against breast cancer. With the FDA's new mandate, women can feel more informed and empowered in their breast health decisions, and Eve Wellness is here to support them every step of the way.
For more information on Eve Wellness and their breast cancer screening services, visit their website at https://www.myevewellness.com/.
Source: Eve Wellness, Inc.
Filed Under: Health
0 Comments
Latest on ncarol.com
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
- Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
- Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
- Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth
- CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
- Goatimus Launches Dynamic Context: AI Prompt Engineering Gets Smarter
- Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
- RNHA Affirms Support for President Trump as Nation Marks Historic Victory for Freedom
- American Laser Study Club Announces 2026 Kumar Patel Prize in Laser Surgery Recipients: Ann Bynum, DDS, and Boaz Man, DVM
- Lineus Medical Completes UK Registration for SafeBreak® Vascular
- Canyons & Chefs Announces Revamped Homepage
- $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
- Really Cool Music Releases Its Fourth Single - "So Many Lost Years"
- MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
- The Wait is Over: Salida Wine Festival Announces Triumphant 2026 Return After Seven-Year Hiatus
- Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
- Tatt:Magic Unveils Breakthrough Tattoo Recovery System with Faster Recovery No Itch, for Vibrant ink
- Anne Seidman: Within the Lines
- How Democrats Made Healthcare More Expensive in 2026
